Hexvix filed in 26 EU countries:
This article was originally published in Clinica
A marketing application for PhotoCure's bladder cancer imaging agent, Hexvix, has been deemed fileable in 26 European countries, the Oslo, Norway firm has reported. Each country has committed to take a decision to recognise the application, which has already been approved in Sweden, within 90 days, the company said. National marketing authorisation in each country will be issued following the approval of the product information for doctors and patients in the local language. Hexvix is designed for use with cystoscopy.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.